Shares of Kane Biotech Inc. (CVE:KNE – Get Free Report) fell 16.7% during trading on Monday . The company traded as low as C$0.02 and last traded at C$0.03. 327,000 shares traded hands during trading, an increase of 81% from the average session volume of 180,592 shares. The stock had previously closed at C$0.03.
Kane Biotech Stock Down 16.7%
The company’s 50 day moving average price is C$0.03 and its two-hundred day moving average price is C$0.03. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17. The firm has a market cap of C$5.13 million, a PE ratio of -2.50 and a beta of 1.06.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
